Turning Genomic Insights into Breakthrough Therapies | Peter Campbell, CSO of Quotient Therapeutics

Follow us at https://signal.nucleate.xyz/

[0:00] Peter begins by discussing his upbringing in a New Zealand university town.

[2:39] He realizes he is not suited for bench work during his PhD and discovers a passion for computational analysis.

[4:30] Campbell joins the Sanger Institute and participates in one of the first cancer genome sequencing projects using new technology.

[8:00] He describes the revolutionary period of cancer genomics from 2008 to 2015, systematically exploring genetic changes in cancers.

[12:32] Campbell shifts research focus to studying mutations in normal tissues across different organ systems.

[13:44] Flagship Pioneering reaches out to discuss the potential clinical relevance of their research.

[14:56] He co-founds Quotient Therapeutics with Flagship Pioneering to explore therapeutic applications of somatic mutation research.

[20:39] Campbell explains the evolutionary process of mutations in cells, comparing it to natural selection.

[26:49] He discusses the incredible genetic diversity within a single individual's cell populations.

[35:12] The conversation explores the potential for personalized medicine based on genetic mutation analysis.

[39:55] Campbell explains how cells adapt to environmental changes and potentially revert mutations when pressures are removed.

[49:29] He describes Quotient's approach to identifying and potentially targeting specific mutations.

[58:47] Campbell discusses the partnership with Pfizer in cardiovascular and renal disease research.

[1:08:01] He compares the differences between academic and startup research environments.

[1:15:39] Campbell offers final advice for entrepreneurs transitioning from academia to startups.